Quoin Pharmaceuticals (QNRX) Expected to Post Quarterly Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.61) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.77) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.40.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX opened at $4.45 on Tuesday. The firm has a market cap of $8.94 million, a PE ratio of -0.15 and a beta of 1.49. The firm’s 50 day moving average price is $4.49 and its 200 day moving average price is $6.42. Quoin Pharmaceuticals has a twelve month low of $3.25 and a twelve month high of $41.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in QNRX. Ikarian Capital LLC acquired a new stake in Quoin Pharmaceuticals in the 4th quarter worth approximately $3,052,000. Millennium Management LLC acquired a new position in Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. SummitTX Capital L.P. bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at approximately $935,000. Boothbay Fund Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at approximately $863,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter valued at approximately $840,000. 8.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity began coverage on shares of Quoin Pharmaceuticals in a research note on Monday, June 15th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Quoin Pharmaceuticals presently has a consensus rating of “Hold”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.